2 recruiting, 1 not yet recruiting, 1 withdrawn. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 2, Not yet recruiting 1, Withdrawn 1 |
Follow Urothelial Carcinoma Recurrent: new trials by email Literature Review of Urothelial Carcinoma Recurrent trials Research Report on Urothelial Carcinoma Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Not yet recruiting | Relmada Therapeutics, Inc. | 393 | 2027-02-01 | 2026-09-02 |
| BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) - Urothelial Cancer, Metastatic Urothelial Cancer | Phase 3 | Recruiting | SystImmune Inc. | 520 | 2026-09-01 | 2026-10-13 |
| A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Withdrawn | Relmada Therapeutics, Inc. | 2026-06-30 | 2026-03-17 | |
| Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus Calmette-Guerin: Strain TICE - Bladder Cancer, Bladder Cancer Recurrent | Phase 3 | Recruiting | Verity Pharmaceuticals Inc. | 540 | 2024-04-24 | 2026-03-20 |
Neoplasms (3) · Urinary Bladder Neoplasms (3) · Urologic Neoplasms (2) · Neoplasm Metastasis (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Recurrence (1)
Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Neoplasms by Site (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Urologic Diseases (4) · Urinary Bladder Diseases (3) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Urologic Neoplasms (2) · Carcinoma (1) · Disease Attributes (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
BCG Vaccine (1) · Carboplatin (1) · Cisplatin (1) · Gemcitabine (1) · Platinum Compounds (1)
Relmada Therapeutics, Inc. (2) · SystImmune Inc. (1) · Verity Pharmaceuticals Inc. (1)
Canada (1) · United States (1)
Alexandre R Zlotta, MD, PhD, FRCSC (1) · Girish S Kulkarni, MD (1) · Jimmy Liu Zhao, MD, PhD (1) · Raj S Pruthi, MD MHA FACS (1)